EDOC:AU:AU-BetaShares Digital Health and Telemedicine ETF (AUD)

ETF | Others |

Last Closing

USD 10.14

Change

0.00 (0.00)%

Market Cap

N/A

Volume

N/A

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-12-26 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
VAS:AU Vanguard Australian Shares

+0.53 (+0.52%)

USD 16.85B
IVV:AU iShares Core S&P 500 AUD

+0.58 (+0.91%)

USD 9.99B
VGS:AU Vanguard MSCI International Sh..

+1.42 (+1.01%)

USD 9.45B
QUAL:AU VanEck Vectors MSCI World ex A..

+0.77 (+1.31%)

USD 6.99B
IOZ:AU Ishares Core S&P/Asx 200

+0.15 (+0.45%)

USD 6.22B
STW:AU SPDR® S&P/ASX 200 Fund

+0.35 (+0.47%)

USD 5.69B
NDQ:AU Betashares Nasdaq 100

+0.68 (+1.32%)

USD 5.22B
HNDQ:AU BetaShares NASDAQ 100 ETF - Cu..

+0.49 (+1.13%)

USD 4.86B
A200:AU BetaShares Australia 200

+0.68 (+0.49%)

USD 4.72B
VTS:AU Vanguard US Total Market Share..

+6.02 (+1.28%)

USD 4.71B

ETFs Containing EDOC:AU

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 5.41% 36% F 62% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 5.41% 26% F 58% F
Trailing 12 Months  
Capital Gain 8.45% 47% F 66% D+
Dividend Return N/A N/A N/A N/A N/A
Total Return 8.45% 37% F 62% D
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -1.91% 14% F 34% F
Dividend Return -1.91% 12% F 32% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 8.12% 65% D 93% A
Risk Adjusted Return -23.56% 11% F 26% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (AUD)

Quarterly Financials (AUD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.